Opus Genetics (IRD) Tax Provisions (2022 - 2025)

Opus Genetics (IRD) posted quarterly Tax Provisions of -$10.4 million for Q4 2025, down 520600.0% quarter-over-quarter from -$2000.0 in Q4 2023.

Opus Genetics (IRD) Tax Provisions (2022 - 2025) Analysis & Trends

Opus Genetics (IRD) has reported Tax Provisions for 3 consecutive years, with -$10.4 million the latest figure, recorded in Q4 2025.

In Q4 2025, Tax Provisions changed N/A year-over-year to -$10.4 million; the TTM figure through Mar 2026 stood at -$10.4 million (changed N/A YoY), while the FY2025 annual figure was -$10.4 million, changed N/A from the prior year.
Tax Provisions retreated to -$10.4 million in Q4 2025 per IRD's latest filing, from -$2000.0 in the prior quarter.
Across five years, Tax Provisions topped out at $315000.0 in Q4 2022 and bottomed at -$10.4 million in Q4 2025.
Historically, Tax Provisions has averaged -$2.5 million across 3 years, with a median of $6000.0 in 2023.
On a YoY basis, Tax Provisions climbed as much as 100.63% in 2023 and fell as far as 100.63% in 2023.
Opus Genetics' Tax Provisions stood at $315000.0 in 2022, then slumped by 100.63% to -$2000.0 in 2023, then tumbled by 520600.0% to -$10.4 million in 2025.
Business Quant data shows IRD's Tax Provisions at -$10.4 million in Q4 2025, -$2000.0 in Q4 2023, and $14000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	292.00 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	230.90 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	59.00 Mn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	75.45 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	267.73
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	13.31 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	1.90 Mn
10	Opus Genetics	298.36 Mn	209.55 Mn	-	-

Download Data